ISLMF (InSilico Medicine Cayman TopCo) EV-to-OCF: -39.47 (As of Aug. 27, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ISLMF InSilico Medicine Cayman TopCo ISLMF
13 GF Score
Price $6.11
! 3 Warning Signs
View Full Analysis

What is InSilico Medicine Cayman TopCo EV-to-OCF?

InSilico Medicine Cayman TopCo ISLMF -1.77% 13 EV-to-OCF is -39.47 as of Aug. 27, 2026. GuruFocus rates ISLMF with a GF Score™ of 13/100. The stock has 3 warning signs investors should review. Among 2,881 Software companies, InSilico Medicine Cayman TopCo ranks better than 90.84% on this metric.

EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, InSilico Medicine Cayman TopCo's Enterprise Value is $3,029.72 Mil. InSilico Medicine Cayman TopCo's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was $-76.77 Mil. Therefore, InSilico Medicine Cayman TopCo's EV-to-OCF for today is -39.47.

The historical rank and industry rank for InSilico Medicine Cayman TopCo's EV-to-OCF or its related term are showing as below:

ISLMF' s EV-to-OCF Range Over the Past 10 Years
Min: -39.6   Med: -1.23   Max: 1.29
Current: -39.6

During the past 4 years, the highest EV-to-OCF of InSilico Medicine Cayman TopCo was 1.29. The lowest was -39.60. And the median was -1.23.

ISLMF's EV-to-OCF is ranked better than
90.84% of 2881 companies
in the Software industry
Industry Median: 6.92 vs ISLMF: -39.60

EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2026-08-27), InSilico Medicine Cayman TopCo's stock price is $6.11. InSilico Medicine Cayman TopCo's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $0.000. Therefore, InSilico Medicine Cayman TopCo's PE Ratio (TTM) for today is N/A.


InSilico Medicine Cayman TopCo  (OTCPK:ISLMF) EV-to-OCF Explanation

EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

InSilico Medicine Cayman TopCo's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=6.11/0.000
=N/A

InSilico Medicine Cayman TopCo's share price for today is $6.11.
InSilico Medicine Cayman TopCo's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.000.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.


InSilico Medicine Cayman TopCo EV-to-OCF Related Terms


InSilico Medicine Cayman TopCo EV-to-OCF Historical Data

* Premium members only.

The historical data trend for InSilico Medicine Cayman TopCo's EV-to-OCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

InSilico Medicine Cayman TopCo EV-to-OCF Chart

InSilico Medicine Cayman TopCo Annual Data
Trend Dec22 Dec23 Dec24 Dec25
EV-to-OCF
0.00 0.00 0.00 -28.99

InSilico Medicine Cayman TopCo Quarterly Data
Dec22 Dec23 Jun24 Dec24 Jun25 Dec25
EV-to-OCF Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 -28.99

ISLMF vs : EV-to-OCF Comparison

For the Software - Infrastructure subindustry, InSilico Medicine Cayman TopCo's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InSilico Medicine Cayman TopCo EV-to-OCF vs Software Industry

For the Software industry and Technology sector, InSilico Medicine Cayman TopCo's EV-to-OCF distribution charts can be found below:

* The bar in red indicates where InSilico Medicine Cayman TopCo's EV-to-OCF falls into.


ISLMF
13GF Score
InSilico Medicine Cayman TopCo ISLMF
EV-to-OCF is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

InSilico Medicine Cayman TopCo EV-to-OCF Calculation

InSilico Medicine Cayman TopCo's EV-to-OCF for today is calculated as:

EV-to-OCF=Enterprise Value (Today)/Cash Flow from Operations (TTM)
=3029.724/-76.766
=-39.47

InSilico Medicine Cayman TopCo's current Enterprise Value is $3,029.72 Mil.
InSilico Medicine Cayman TopCo's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-76.77 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EV-to-OCF →
What does a EV-to-OCF of -39.47 mean?
InSilico Medicine Cayman TopCo (ISLMF) has a EV-to-OCF of -39.47 as of Aug. 27, 2026. According to the industry distribution chart, InSilico Medicine Cayman TopCo ranks #264 out of 2881 companies in the Software industry, placing it in the top 9.2%.
Is InSilico Medicine Cayman TopCo's EV-to-OCF too high?
InSilico Medicine Cayman TopCo's current EV-to-OCF is -39.47. Based on the distribution chart, InSilico Medicine Cayman TopCo ranks #264 out of 2881 companies in the Software industry, which is in the top quartile — a strong position relative to peers. Overall, InSilico Medicine Cayman TopCo has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does InSilico Medicine Cayman TopCo's EV-to-OCF compare to ?
According to the Software industry distribution chart, InSilico Medicine Cayman TopCo ranks #264 out of 2881 companies for EV-to-OCF. This places InSilico Medicine Cayman TopCo in the top 9% of its industry — outperforming the majority of peers. The industry median EV-to-OCF is 6.92. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Software company?
The median EV-to-OCF among Software companies is 6.92, based on 2,881 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Software industry, the median EV-to-OCF is 6.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. InSilico Medicine Cayman TopCo's current EV-to-OCF is -39.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InSilico Medicine Cayman TopCo stock overvalued right now?
InSilico Medicine Cayman TopCo (ISLMF) has a current EV-to-OCF of -39.47. The current EV-to-OCF is -39.47. InSilico Medicine Cayman TopCo's overall GF Score™ is 13/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For InSilico Medicine Cayman TopCo (ISLMF), the current EV-to-OCF is -39.47 as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

InSilico Medicine Cayman TopCo Business Description

Comparable Companies
Other Exchanges 03696:Hong KongO15:Germany
Address Hong Kong Science Park, Unit 310, 3rd Floor, Building 8W, Phase 2, Pak Shek Kok, New Territories, Hong Kong, HKG
InSilico Medicine Cayman TopCo is engaged in applying artificial intelligence (AI) solutions to drug discovery and development by leveraging its proprietary platforms. It has generated multiple clinical-stage or IND-enabling assets using Pharma.AI, an AI-enabled platform that supports drug discovery and development activities. The company operates under a project-based business model, deriving revenue from out-licensing and collaboration arrangements. Geographically, the company generates revenue from multiple countries, with the majority of the revenue coming from United States.
13GF Score

Get the complete analysis for ISLMF

EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.11
Price